NASDAQ:FGEN - FibroGen Stock Price, Price Target & More

Get Started

$51.65 +0.20 (+0.39 %)

(As of 05/25/2018 04:00 PM ET)

Previous Close$51.65

Today's Range$50.55 - $52.10

52-Week Range$25.35 - $63.00

Volume303,585 shs

Average Volume443,056 shs

Market Capitalization$4.30 billion

P/E Ratio-29.86

Dividend YieldN/A

Beta1.9

About FibroGen (NASDAQ:FGEN)

FibroGen, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200, a corneal implant medical device for the treatment of corneal blindness resulting from partial thickness corneal damage. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was incorporated in 1993 and is headquartered in San Francisco, California.

Receive FGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for FGEN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

SymbolNASDAQ:FGEN

CUSIPN/A

Webwww.fibrogen.com

Phone415-978-1200

Debt

Debt-to-Equity Ratio0.19

Current Ratio8.61

Quick Ratio8.61

Price-To-Earnings

Trailing P/E Ratio-29.86

Forward P/E Ratio-32.69

P/E GrowthN/A

Sales & Book Value

Annual Sales$125.67 million

Price / Sales34.33

Cash FlowN/A

Price / CashN/A

Book Value$6.21 per share

Price / Book8.32

Profitability

EPS (Most Recent Fiscal Year)($1.73)

Net Income$-126,200,000.00

Net Margins-102.86%

Return on Equity-27.70%

Return on Assets-16.78%

Miscellaneous

Employees423

Outstanding Shares83,520,000

FibroGen (NASDAQ:FGEN) Frequently Asked Questions

What is FibroGen's stock symbol?

FibroGen trades on the NASDAQ under the ticker symbol "FGEN."

How were FibroGen's earnings last quarter?

FibroGen (NASDAQ:FGEN) issued its quarterly earnings data on Tuesday, February, 27th. The biopharmaceutical company reported ($0.27) EPS for the quarter, beating the Zacks' consensus estimate of ($0.28) by $0.01. The biopharmaceutical company had revenue of $42.51 million for the quarter, compared to analyst estimates of $45.37 million. FibroGen had a negative return on equity of 27.70% and a negative net margin of 102.86%. View FibroGen's Earnings History.

When is FibroGen's next earnings date?

FibroGen is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for FibroGen.

What price target have analysts set for FGEN?

7 equities research analysts have issued twelve-month target prices for FibroGen's stock. Their predictions range from $31.00 to $88.00. On average, they expect FibroGen's stock price to reach $66.6667 in the next year. View Analyst Ratings for FibroGen.

What are Wall Street analysts saying about FibroGen stock?

Here are some recent quotes from research analysts about FibroGen stock:

1. Mizuho analysts commented, "We expect to see top-line phase 3 data from Disease (CKD) in 4Q18 and a potential regulatory approval in China is expected by year-end 2018. We upgrade to Buy and maintain our $61 PT as we believe the company is likely to gain the first approval in new generation anemia drugs. If Pamrevlumab reproduces its Phase II results in the planned Phase III trial, we see significant upside." (5/15/2018)
2. According to Zacks Investment Research, "FibroGen, Inc. is a research-based biotechnology company. It is focused on the discovery, development, and commercialization of therapeutic agents for treatment of anemia, fibrosis, cancer, and other serious unmet medical needs. The Company develops Roxadustat that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; and FG-3019 which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and liver fibrosis. FibroGen, Inc. is headquartered in San Francisco, California. " (5/14/2018)

Who are some of FibroGen's key competitors?

Some companies that are related to FibroGen include BioMarin Pharmaceutical (BMRN), Grifols (GRFS), UCB (UCBJF), Ono Pharmaceutical (OPHLF), Nektar Therapeutics (NKTR), Genmab (GNMSF), Merck Group (MKGAF), Perrigo (PRGO), BeiGene (BGNE), Alnylam Pharmaceuticals (ALNY), Jazz Pharmaceuticals (JAZZ), Valeant Pharmaceuticals Intl (VRX), SAGE Therapeutics (SAGE), Alkermes (ALKS) and Sarepta Therapeutics (SRPT).

Who are FibroGen's key executives?

FibroGen's management team includes the folowing people:

Mr. Thomas B. Neff, Founder, Chairman & CEO (Age 64)
Mr. Pat Cotroneo, VP of Fin. & CFO (Age 54)
Dr. K. Peony Yu M.D., Chief Medical Officer (Age 56)
Dr. Barry A. Berkowitz, Founder
Dr. Michael J. Martinelli Ph.D., VP of Technical Devel.

When did FibroGen IPO?

(FGEN) raised $146 million in an initial public offering (IPO) on Friday, November 14th 2014. The company issued 8,100,000 shares at $18.00 per share. Goldman Sachs, Citigroup and Leerink Partners served as the underwriters for the IPO and RBC Capital Markets, Stifel and William Blair were co-managers.

Has FibroGen been receiving favorable news coverage?

Press coverage about FGEN stock has been trending positive recently, according to Accern. Accern identifies positive and negative news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. FibroGen earned a daily sentiment score of 0.30 on Accern's scale. They also assigned media stories about the biopharmaceutical company an impact score of 44.00 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near term.

Who are FibroGen's major shareholders?

FibroGen's stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.09%), Farallon Capital Management LLC (2.06%), JPMorgan Chase & Co. (1.16%), Northern Trust Corp (1.00%), Eagle Asset Management Inc. (0.98%) and Lord Abbett & CO. LLC (0.69%). Company insiders that own FibroGen stock include Gerald Lema, Jorma Routti, K Peony Yu, Kalevi Kurkijarvi, Pat Cotroneo, Roberto Pedro Rosenkranz, Rory B Riggs, Thomas B Neff, Thomas F Kearns Jr and Toshinari Tamura. View Institutional Ownership Trends for FibroGen.

Which institutional investors are selling FibroGen stock?

FGEN stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., JPMorgan Chase & Co., Sphera Funds Management LTD., Citigroup Inc., Nexthera Capital LP, Wells Fargo & Company MN, Pinnacle Associates Ltd. and Dimensional Fund Advisors LP. Company insiders that have sold FibroGen company stock in the last year include Jorma Routti, K Peony Yu, Kalevi Kurkijarvi, Pat Cotroneo, Roberto Pedro Rosenkranz, Rory B Riggs, Thomas B Neff, Thomas F Kearns Jr and Toshinari Tamura. View Insider Buying and Selling for FibroGen.

Which institutional investors are buying FibroGen stock?

FGEN stock was purchased by a variety of institutional investors in the last quarter, including PointState Capital LP, Artal Group S.A., UBS Group AG, Amundi Pioneer Asset Management Inc., Lord Abbett & CO. LLC, BNP Paribas Arbitrage SA, Millennium Management LLC and Prudential Financial Inc.. View Insider Buying and Selling for FibroGen.

How do I buy shares of FibroGen?

Shares of FGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is FibroGen's stock price today?

One share of FGEN stock can currently be purchased for approximately $51.65.

How big of a company is FibroGen?

FibroGen has a market capitalization of $4.30 billion and generates $125.67 million in revenue each year. The biopharmaceutical company earns $-126,200,000.00 in net income (profit) each year or ($1.73) on an earnings per share basis. FibroGen employs 423 workers across the globe.

How can I contact FibroGen?

FibroGen's mailing address is 409 ILLINOIS STREET, SAN FRANCISCO CA, 94158. The biopharmaceutical company can be reached via phone at 415-978-1200 or via email at [email protected]

MarketBeat Community Rating for FibroGen (FGEN)

Community Ranking:		2.6 out of 5 ( )
Outperform Votes:		166 (Vote Outperform)
Underperform Votes:		148 (Vote Underperform)
Total Votes:		314

MarketBeat's community ratings are surveys of what our community members think about FibroGen and other stocks. Vote "Outperform" if you believe FGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.

FibroGen (NASDAQ:FGEN) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

7 Wall Street analysts have issued ratings and price targets for FibroGen in the last 12 months. Their average twelve-month price target is $66.6667, suggesting that the stock has a possible upside of 29.07%. The high price target for FGEN is $88.00 and the low price target for FGEN is $31.00. There are currently 1 hold rating, 5 buy ratings and 1 strong buy rating for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	3.00	2.86	2.86	2.88
Ratings Breakdown:	0 Sell Rating(s) 1 Hold Rating(s) 5 Buy Rating(s) 1 Strong Buy Rating(s)	0 Sell Rating(s) 2 Hold Rating(s) 4 Buy Rating(s) 1 Strong Buy Rating(s)	0 Sell Rating(s) 2 Hold Rating(s) 4 Buy Rating(s) 1 Strong Buy Rating(s)	0 Sell Rating(s) 2 Hold Rating(s) 5 Buy Rating(s) 1 Strong Buy Rating(s)
Consensus Price Target:	$66.6667	$66.6667	$65.6667	$65.6667
Price Target Upside:	29.07% upside	44.30% upside	21.49% upside	21.49% upside

FibroGen (NASDAQ:FGEN) Consensus Price Target History

Price Target History for FibroGen (NASDAQ:FGEN)

FibroGen (NASDAQ:FGEN) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
5/15/2018	Mizuho	Upgrade	Neutral ➝ Buy	$61.00	High
2/28/2018	Leerink Swann	Reiterated Rating	Outperform	$80.00 ➝ $88.00	High
9/14/2017	Stifel Nicolaus	Reiterated Rating	Buy	$80.00	Low
9/12/2017	Jefferies Group	Reiterated Rating	Buy	$75.00	Low
8/9/2017	William Blair	Reiterated Rating	Outperform		Medium
8/8/2017	Citigroup	Boost Price Target	Top Pick	$48.00 ➝ $65.00	High
7/21/2017	Goldman Sachs Group	Downgrade	Buy ➝ Neutral	$31.00	Medium
1/18/2017	Royal Bank of Canada	Reiterated Rating	Buy		N/A
8/9/2016	Credit Suisse Group	Reiterated Rating	Buy	$37.00	N/A

(Data available from 5/26/2016 forward)

FibroGen (NASDAQ:FGEN) Earnings History and Estimates Chart

Earnings by Quarter for FibroGen (NASDAQ:FGEN)

FibroGen (NASDAQ:FGEN) Earnings Estimates

2018 EPS Consensus Estimate: ($1.46)
2019 EPS Consensus Estimate: $1.08

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	3	($0.52)	($0.48)	($0.50)
Q2 2018	3	($0.56)	($0.50)	($0.53)
Q3 2018	3	($0.58)	$0.00	($0.38)
Q4 2018	3	($0.68)	$0.59	($0.05)
Q1 2019	1	$2.63	$2.63	$2.63
Q2 2019	1	($0.79)	($0.79)	($0.79)
Q3 2019	1	($0.77)	($0.77)	($0.77)
Q4 2019	1	$0.01	$0.01	$0.01

FibroGen (NASDAQ FGEN) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
8/6/2018		($0.55)					N/A
5/9/2018	Q1 2018	($0.51)	($0.50)	$29.07 million	$31.90 million	View	N/A
2/27/2018	Q4 2017	($0.28)	($0.27)	$45.37 million	$42.51 million	View	N/A
11/8/2017	Q3 2017	($0.37)	($0.50)	$41.34 million	$27.27 million	View	N/A
8/7/2017	Q2 2017	($0.47)	($0.48)	$34.80 million	$29.00 million	View	Listen
5/9/2017	Q1 2017	($0.63)	($0.52)	$26.02 million	$26.89 million	View	Listen
3/1/2017	Q4 2016	($0.53)	($0.54)	$19.29 million	$31.91 million	View	Listen
11/8/2016	Q3	($0.63)	($0.38)	$24.30 million	$30.10 million	View	Listen
8/8/2016	Q2	$0.36	$0.35	$80.58 million	$89.28 million	View	Listen
5/9/2016	Q116	($0.56)	($0.45)	$16.89 million	$28.28 million	View	Listen
2/29/2016	Q4	($0.54)	($0.85)	$40.44 million	$24.44 million	View	Listen
11/12/2015	Q3	($0.6050)	($0.74)	$28.74 million	$19.54 million	View	Listen
8/13/2015	Q215	$0.73	$0.83	$111.75 million	$120.55 million	View	Listen
5/12/2015	Q115	($0.53)	($0.78)	$34.00 million	$16.30 million	View	N/A
3/26/2015	Q414	($0.90)	($0.82)	$16.49 million	$16.11 million	View	Listen

(Earnings results data provided by Zacks Investment Research)

FibroGen (NASDAQ:FGEN) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

FibroGen (NASDAQ FGEN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 8.96%
Institutional Ownership Percentage: 63.47%

Insider Trading History for FibroGen (NASDAQ:FGEN)

Institutional Ownership by Quarter for FibroGen (NASDAQ:FGEN)

FibroGen (NASDAQ FGEN) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/21/2018	Pat Cotroneo	SVP	Sell	14,987	$55.04	$824,884.48
5/17/2018	Kalevi Kurkijarvi	Director	Sell	4,000	$51.83	$207,320.00
5/17/2018	Thomas B Neff	CEO	Sell	39,636	$51.82	$2,053,937.52
5/9/2018	Jorma Routti	Director	Sell	6,000	$47.10	$282,600.00	133,840
5/3/2018	Thomas B Neff	CEO	Sell	39,636	$47.04	$1,864,477.44	2,916,493
4/19/2018	Kalevi Kurkijarvi	Director	Sell	4,000	$47.69	$190,760.00	24,000
4/18/2018	Thomas B Neff	CEO	Sell	39,636	$48.56	$1,924,724.16	2,933,653
4/16/2018	K Peony Yu	Insider	Sell	7,500	$47.81	$358,575.00	156,233
4/9/2018	Jorma Routti	Director	Sell	6,000	$46.59	$279,540.00	133,840
4/5/2018	Thomas B Neff	CEO	Sell	39,636	$45.59	$1,807,005.24	2,950,813
3/21/2018	Thomas B Neff	CEO	Sell	39,636	$50.95	$2,019,454.20	2,969,251
3/15/2018	Pat Cotroneo	VP	Sell	42,026	$52.85	$2,221,074.10	168,334
3/15/2018	Roberto Pedro Rosenkranz	Director	Sell	1,000	$52.34	$52,340.00	24,000
3/14/2018	K Peony Yu	Insider	Sell	9,891	$53.20	$526,201.20	128,333
3/13/2018	Pat Cotroneo	CFO	Sell	5,932	$54.61	$323,946.52	168,334
3/12/2018	Thomas F Kearns Jr	Director	Sell	18,000	$55.00	$990,000.00	135,064
3/9/2018	Rory B Riggs	Director	Sell	22,905	$55.75	$1,276,953.75	411,295
3/8/2018	Pat Cotroneo	VP	Sell	1,894	$53.12	$100,609.28	176,160
3/8/2018	Thomas B Neff	CEO	Sell	39,636	$53.14	$2,106,257.04	2,907,425
2/23/2018	Thomas B Neff	CEO	Sell	39,636	$56.66	$2,245,775.76	2,955,614
2/16/2018	Pat Cotroneo	VP	Sell	49,500	$55.96	$2,770,020.00	207,392
2/15/2018	Kalevi Kurkijarvi	Director	Sell	6,000	$55.69	$334,140.00	26,000
2/8/2018	K Peony Yu	Insider	Sell	7,500	$53.97	$404,775.00	144,986
1/30/2018	Thomas B Neff	CEO	Sell	38,636	$61.40	$2,372,250.40	2,958,105
1/29/2018	K Peony Yu	Insider	Sell	10,000	$62.00	$620,000.00	152,086
1/26/2018	Roberto Pedro Rosenkranz	Director	Sell	6,000	$60.00	$360,000.00	29,000
1/22/2018	Pat Cotroneo	CFO	Sell	25,000	$48.72	$1,218,000.00	208,852
1/22/2018	Roberto Pedro Rosenkranz	Director	Sell	71	$50.00	$3,550.00	36,929
1/18/2018	Kalevi Kurkijarvi	Director	Sell	6,000	$47.38	$284,280.00	28,000
1/18/2018	Thomas B Neff	CEO	Sell	18,900	$47.64	$900,396.00	2,981,447
1/5/2018	Thomas B Neff	CEO	Sell	38,636	$47.61	$1,839,459.96	3,029,887
12/29/2017	Thomas B Neff	CEO	Sell	38,636	$48.39	$1,869,596.04
12/28/2017	Thomas B Neff	CEO	Sell	18,900	$48.29	$912,681.00	3,071,705
12/21/2017	Thomas B Neff	CEO	Sell	38,636	$44.66	$1,725,483.76	3,022,934
12/18/2017	Kalevi Kurkijarvi	Director	Sell	2,000	$42.80	$85,600.00	22,000
12/14/2017	K Peony Yu	Insider	Sell	2,851	$43.70	$124,588.70	162,086
12/14/2017	Thomas B Neff	CEO	Sell	18,900	$42.71	$807,219.00	3,060,887
12/12/2017	Kalevi Kurkijarvi	Director	Sell	12,000	$44.45	$533,400.00	36,000
12/11/2017	Pat Cotroneo	VP	Sell	2,851	$46.00	$131,146.00	183,852
12/4/2017	Gerald Lema	Director	Buy	3,500	$46.70	$163,450.00	3,500
12/1/2017	Jorma Routti	Director	Sell	12,000	$47.25	$567,000.00	133,840
11/17/2017	Kalevi Kurkijarvi	Director	Sell	2,000	$46.65	$93,300.00	24,000
11/16/2017	Thomas B Neff	CEO	Sell	18,900	$46.60	$880,740.00	3,109,555
11/15/2017	Thomas F Kearns Jr	Director	Sell	18,000	$45.22	$813,960.00	156,564
11/6/2017	K Peony Yu	Insider	Sell	7,500	$55.37	$415,275.00	170,104
10/31/2017	Thomas B Neff	CEO	Sell	38,636	$56.13	$2,168,638.68	3,144,573
10/17/2017	Kalevi Kurkijarvi	Director	Sell	2,000	$52.24	$104,480.00	26,000
10/17/2017	Thomas B Neff	CEO	Sell	38,636	$55.02	$2,125,752.72	3,176,861
10/16/2017	Thomas B Neff	CEO	Sell	18,900	$54.83	$1,036,287.00	3,176,861
10/4/2017	K Peony Yu	Insider	Sell	15,000	$60.00	$900,000.00
10/3/2017	Thomas B Neff	CEO	Sell	38,636	$55.09	$2,128,457.24
10/2/2017	K Peony Yu	Insider	Sell	40,000	$54.63	$2,185,200.00
10/2/2017	Thomas B Neff	CEO	Sell	18,900	$54.45	$1,029,105.00	3,217,455
9/20/2017	Thomas B Neff	CEO	Sell	38,636	$53.46	$2,065,480.56	3,246,754
9/18/2017	Kalevi Kurkijarvi	Director	Sell	4,000	$46.65	$186,600.00	30,000
9/14/2017	K Peony Yu	Insider	Sell	2,851	$51.00	$145,401.00	185,546
9/14/2017	Thomas B Neff	CEO	Sell	38,636	$51.67	$1,996,322.12	3,297,655
9/13/2017	Rory B Riggs	Director	Sell	25,000	$51.92	$1,298,000.00	435,200
9/13/2017	Thomas B Neff	CEO	Sell	18,900	$51.29	$969,381.00	3,297,655
9/11/2017	Pat Cotroneo	VP	Sell	2,851	$49.45	$140,981.95	157,405
9/1/2017	Jorma Routti	Director	Sell	12,000	$47.36	$568,320.00	133,840
8/29/2017	Thomas B Neff	CEO	Sell	38,636	$43.73	$1,689,552.28	3,330,780
8/28/2017	Thomas B Neff	CEO	Sell	18,900	$43.04	$813,456.00	3,330,780
8/21/2017	K Peony Yu	Insider	Sell	7,500	$41.03	$307,725.00	191,507
8/17/2017	Kalevi Kurkijarvi	Director	Sell	2,000	$40.74	$81,480.00	30,000
8/8/2017	K Peony Yu	Insider	Sell	37,500	$50.58	$1,896,750.00	236,507
8/8/2017	Pat Cotroneo	VP	Sell	95,000	$50.61	$4,807,950.00	173,366
8/2/2017	Pat Cotroneo	VP	Sell	28,346	$33.97	$962,913.62	170,666
8/1/2017	K Peony Yu	Insider	Sell	10,000	$33.48	$334,800.00	226,507
7/25/2017	Thomas B Neff	CEO	Sell	38,636	$35.09	$1,355,737.24	3,330,780
7/24/2017	Thomas B Neff	CEO	Sell	18,900	$35.06	$662,634.00	3,330,780
7/17/2017	Kalevi Kurkijarvi	Director	Sell	2,000	$33.45	$66,900.00	32,000
7/10/2017	K Peony Yu	Insider	Sell	5,000	$32.98	$164,900.00	216,507
7/7/2017	Thomas B Neff	CEO	Sell	38,636	$33.38	$1,289,669.68	3,330,780
7/6/2017	Pat Cotroneo	VP	Sell	4,000	$34.00	$136,000.00	167,366
7/6/2017	Thomas B Neff	CEO	Sell	18,900	$33.53	$633,717.00	3,330,780
6/22/2017	Pat Cotroneo	VP	Sell	3,000	$32.00	$96,000.00	166,366
6/22/2017	Thomas B Neff	CEO	Sell	38,636	$31.52	$1,217,806.72	3,330,780
6/19/2017	Pat Cotroneo	VP	Sell	5,500	$30.00	$165,000.00	168,866
6/16/2017	Thomas B Neff	CEO	Sell	38,636	$29.40	$1,135,898.40	3,330,780
6/15/2017	Kalevi Kurkijarvi	Director	Sell	2,000	$28.50	$57,000.00	34,000
6/14/2017	K Peony Yu	Insider	Sell	3,721	$28.95	$107,722.95	221,507
6/12/2017	Pat Cotroneo	VP	Sell	2,891	$28.75	$83,116.25	163,366
6/12/2017	Toshinari Tamura	Director	Sell	30,000	$28.89	$866,700.00	60,000
6/6/2017	Thomas F Kearns Jr	Director	Sell	18,000	$28.71	$516,780.00	156,564
5/31/2017	Thomas B Neff	CEO	Sell	38,636	$26.21	$1,012,649.56	3,345,941
5/16/2017	Kalevi Kurkijarvi	Director	Sell	2,000	$27.40	$54,800.00	36,000
5/16/2017	Thomas B Neff	CEO	Sell	38,636	$27.70	$1,070,217.20	3,345,941
5/15/2017	Thomas B Neff	CEO	Sell	18,900	$27.75	$524,475.00	3,345,941
5/10/2017	K Peony Yu	Insider	Sell	5,000	$26.38	$131,900.00	227,346
4/25/2017	K Peony Yu	Insider	Sell	5,000	$28.00	$140,000.00	236,046
4/25/2017	Pat Cotroneo	VP	Sell	6,500	$28.00	$182,000.00	164,405
4/25/2017	Thomas B Neff	CEO	Sell	38,636	$26.92	$1,040,081.12	3,345,941
4/24/2017	Thomas B Neff	CEO	Sell	18,900	$26.35	$498,015.00	3,345,941
4/17/2017	Kalevi Kurkijarvi	Director	Sell	2,000	$25.25	$50,500.00	38,000
4/13/2017	Thomas B Neff	CEO	Sell	38,636	$24.79	$957,786.44	3,345,941
4/4/2017	Thomas B Neff	CEO	Sell	38,636	$23.92	$924,173.12	3,345,941
3/21/2017	Thomas B Neff	CEO	Sell	38,636	$24.34	$940,400.24	3,345,941
3/20/2017	Thomas B Neff	CEO	Sell	18,900	$24.88	$470,232.00	3,345,941
3/15/2017	Thomas B Neff	CEO	Sell	38,636	$25.07	$968,604.52	3,353,983
2/16/2017	Kalevi Kurkijarvi	Director	Sell	2,000	$24.45	$48,900.00	40,000
2/14/2017	Thomas B Neff	CEO	Sell	38,636	$23.94	$924,945.84	3,274,061
2/13/2017	Thomas B Neff	CEO	Sell	18,900	$23.97	$453,033.00	3,274,061
2/9/2017	Thomas B Neff	CEO	Sell	37,798	$23.46	$886,741.08	3,278,868
1/27/2017	Thomas B Neff	CEO	Sell	37,798	$23.29	$880,315.42	3,288,484
1/19/2017	Kalevi Kurkijarvi	Director	Sell	2,000	$24.90	$49,800.00	42,000
1/12/2017	Thomas B Neff	CEO	Sell	37,798	$23.85	$901,482.30	3,298,100
1/11/2017	Pat Cotroneo	VP	Sell	6,500	$24.00	$156,000.00	138,748
1/10/2017	K Peony Yu	Insider	Sell	5,000	$23.56	$117,800.00	202,448
12/28/2016	Thomas B Neff	CEO	Sell	37,798	$20.74	$783,930.52	3,307,718
12/16/2016	Rory B Riggs	Director	Sell	20,000	$20.87	$417,400.00	460,200
12/13/2016	Thomas B Neff	CEO	Sell	37,798	$21.24	$802,829.52	3,317,334
12/12/2016	Pat Cotroneo	VP	Sell	2,344	$22.05	$51,685.20	132,248
12/12/2016	Thomas B Neff	CEO	Sell	18,899	$21.48	$405,950.52	3,317,334
11/29/2016	Thomas B Neff	CEO	Sell	37,798	$22.80	$861,794.40	3,331,639
11/28/2016	Thomas B Neff	CEO	Sell	18,899	$22.74	$429,763.26	3,331,639
11/18/2016	Thomas F Kearns Jr	Director	Sell	18,000	$22.40	$403,200.00	165,564
11/17/2016	Thomas B Neff	CEO	Sell	37,798	$22.29	$842,517.42	3,341,255
11/1/2016	Thomas B Neff	CEO	Sell	37,798	$16.76	$633,494.48	3,350,871
10/19/2016	Thomas B Neff	CEO	Sell	37,798	$17.75	$670,914.50	3,360,487
10/18/2016	Thomas B Neff	CEO	Sell	18,899	$17.94	$339,048.06	3,360,487
10/4/2016	Thomas B Neff	CEO	Sell	18,899	$20.67	$390,642.33	3,370,103
10/3/2016	Thomas B Neff	CEO	Sell	18,899	$20.55	$388,374.45	3,370,103
9/21/2016	Thomas B Neff	CEO	Sell	37,798	$21.66	$818,704.68	3,379,719
9/14/2016	K Peony Yu	Insider	Sell	2,345	$18.66	$43,757.70	206,502
9/12/2016	Pat Cotroneo	VP	Sell	2,345	$18.22	$42,725.90	134,359
9/9/2016	Thomas B Neff	CEO	Sell	37,798	$18.99	$717,784.02	3,389,335
8/26/2016	Thomas B Neff	CEO	Sell	37,798	$17.80	$672,804.40	3,403,639
7/27/2016	Thomas B Neff	CEO	Sell	37,798	$18.38	$694,727.24	3,413,255
7/13/2016	Thomas B Neff	CEO	Sell	27,000	$17.50	$472,500.00	3,412,664
6/29/2016	Thomas B Neff	CEO	Sell	27,000	$16.02	$432,540.00	3,439,764
6/15/2016	Pat Cotroneo	CFO	Sell	1,796	$16.49	$29,616.04	138,114
6/15/2016	Thomas B Neff	CEO	Sell	27,000	$16.48	$444,960.00	3,466,664
6/10/2016	K Peony Yu	Insider	Sell	2,344	$17.96	$42,098.24	210,257
6/3/2016	Thomas B Neff	CEO	Sell	27,000	$18.99	$512,730.00	3,507,164
5/20/2016	Thomas B Neff	CEO	Sell	27,000	$17.68	$477,360.00	3,526,053
5/16/2016	Pat Cotroneo	CFO	Sell	6,107	$17.60	$107,483.20	141,868
5/3/2016	Thomas B Neff	CEO	Sell	27,000	$17.78	$480,060.00	3,552,353
4/20/2016	Thomas B Neff	CEO	Sell	27,000	$19.98	$539,460.00	3,579,353
4/19/2016	Thomas B Neff	CEO	Sell	13,500	$20.21	$272,835.00	3,579,353
4/5/2016	Thomas B Neff	CEO	Sell	27,000	$21.11	$569,970.00	3,606,353
4/1/2016	Frank H Md Valone	Insider	Sell	10,750	$21.11	$226,932.50	115,434
3/22/2016	Thomas B Neff	CEO	Sell	27,000	$18.74	$505,980.00	3,633,453
3/8/2016	Thomas B Neff	CEO	Sell	27,000	$19.62	$529,740.00	3,667,175
3/1/2016	Frank H Md Valone	Insider	Sell	10,750	$16.84	$181,030.00	115,133
2/23/2016	Thomas B Neff	CEO	Sell	27,000	$19.11	$515,970.00	3,596,207
2/22/2016	Thomas B Neff	CEO	Sell	13,500	$19.81	$267,435.00	3,596,207
2/16/2016	Frank H. Md Valone	insider	Sell	10,750	$18.41	$197,907.50	96,840
2/10/2016	Thomas B. Neff	CEO	Sell	27,000	$15.31	$413,370.00	3,609,407
1/29/2016	Thomas B. Neff	CEO	Sell	27,000	$19.41	$524,070.00	3,636,407
1/21/2016	Thomas F Kearns Jr	Director	Sell	1,572	$22.08	$34,709.76	160,564
1/14/2016	Thomas B. Neff	CEO	Sell	27,000	$23.69	$639,630.00	3,663,407
12/24/2015	Thomas F. Kearns, Jr.	Director	Sell	7,800	$30.88	$240,864.00	162,136
12/23/2015	Thomas B. Neff	CEO	Sell	27,000	$30.10	$812,700.00	3,690,407
12/11/2015	Thomas B. Neff	CEO	Sell	27,000	$29.59	$798,930.00	3,717,407
12/10/2015	K Peony Yu	VP	Sell	1,093	$28.96	$31,653.28	176,595
12/8/2015	Miguel Madero	Director	Sell	40,386	$30.49	$1,231,369.14	55,614
11/30/2015	K Peony Yu	VP	Sell	5,000	$30.00	$150,000.00	178,345
11/25/2015	Pat Cotroneo	CFO	Sell	5,000	$30.00	$150,000.00	107,775
11/24/2015	Thomas B. Neff	CEO	Sell	13,500	$28.98	$391,230.00	3,746,689
11/24/2015	Thomas F. Kearns, Jr.	Director	Sell	3,900	$29.00	$113,100.00	169,936
11/23/2015	Thomas B. Neff	CEO	Sell	13,500	$27.99	$377,865.00	3,746,689
11/23/2015	Thomas F. Kearns, Jr.	Director	Sell	3,900	$28.02	$109,278.00	169,936
11/17/2015	K Peony Yu	VP	Sell	5,000	$28.00	$140,000.00	183,345
11/10/2015	K Peony Yu	VP	Sell	5,000	$25.62	$128,100.00	187,904
11/9/2015	K Peony Yu	VP	Sell	2,500	$25.00	$62,500.00	187,904
11/2/2015	Frank H. Md Valone	insider	Sell	10,000	$23.18	$231,800.00	84,044
10/30/2015	Thomas B. Neff	CEO	Sell	27,000	$24.06	$649,620.00	3,773,689
10/21/2015	Thomas F. Kearns, Jr.	Director	Sell	7,800	$23.83	$185,874.00	177,736
10/19/2015	Frank H. Md Valone	insider	Sell	10,000	$23.00	$230,000.00	84,044
10/19/2015	K Peony Yu	VP	Sell	5,000	$24.00	$120,000.00	192,904
10/16/2015	K Peony Yu	VP	Sell	5,000	$21.46	$107,300.00	197,904
10/16/2015	Thomas B. Neff	CEO	Sell	27,000	$21.86	$590,220.00	3,800,689
10/2/2015	Thomas B. Neff	CEO	Sell	27,000	$21.59	$582,930.00	3,827,689
10/1/2015	Frank H. Md Valone	insider	Sell	10,000	$21.38	$213,800.00	84,044
9/18/2015	Thomas B. Neff	CEO	Sell	27,000	$29.10	$785,700.00	3,854,689
9/15/2015	Pat Cotroneo	CFO	Sell	1,093	$27.95	$30,549.35	107,498
9/14/2015	Rory B. Riggs	Director	Sell	50,000	$27.61	$1,380,500.00	480,200
9/11/2015	Miguel Madero	Director	Sell	20,600	$27.66	$569,796.00	12,000
9/10/2015	K Peony Yu	VP	Sell	1,093	$27.84	$30,429.12	202,904
9/10/2015	Pat Cotroneo	CFO	Sell	7,500	$27.33	$204,975.00	107,251
9/4/2015	Thomas B. Neff	CEO	Sell	13,500	$22.88	$308,880.00	3,862,751
9/3/2015	Thomas B. Neff	CEO	Sell	13,500	$22.92	$309,420.00	3,866,782
9/1/2015	Frank H. Md Valone	insider	Sell	10,000	$23.58	$235,800.00	84,044
7/23/2015	Thomas B Neff	CEO	Sell	27,000	$24.71	$667,170.00
7/20/2015	Frank H Md Valone	Insider	Sell	1,000	$23.70	$23,700.00
7/20/2015	Pat Cotroneo	CFO	Sell	7,881	$23.47	$184,967.07
7/9/2015	Thomas B Neff	CEO	Sell	27,000	$22.11	$596,970.00
7/6/2015	K Peony Yu	VP	Sell	5,381	$22.69	$122,094.89
6/25/2015	Thomas B Neff	CEO	Sell	27,000	$23.57	$636,390.00

(Data available from 1/1/2013 forward)

FibroGen (NASDAQ FGEN) News Headlines

Source:

Date	Headline
	Form 4 FIBROGEN INC For: May 21 Filed by: Cotroneo Pat www.streetinsider.com - May 24 at 9:08 AM
	Pat Cotroneo Sells 14,987 Shares of FibroGen (FGEN) Stock www.americanbankingnews.com - May 23 at 10:26 PM
	A 3-Way Race To The Next Generation IPF Drug: Galapagos, FibroGen, ProMetic seekingalpha.com - May 23 at 4:50 PM
	Fibrogen Makes A Strong Case As An Acquisition Target After Latest Lung Fibrosis Data seekingalpha.com - May 22 at 9:03 AM
	FibroGen Presents Latest Data From PRAISE Phase 2b Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis at ... www.globenewswire.com - May 21 at 4:37 PM
	FibroGen's pamrevlumab shows treatment effect in mid-stage IPF study; shares up 2% after hours seekingalpha.com - May 21 at 4:37 PM
	FibroGen Presents Latest Data From PRAISE Phase 2b Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis at American Thoracic Society 2018 finance.yahoo.com - May 21 at 4:37 PM
	$28.28 Million in Sales Expected for FibroGen (FGEN) This Quarter www.americanbankingnews.com - May 19 at 3:58 AM
	Kalevi Kurkijarvi Sells 4,000 Shares of FibroGen (FGEN) Stock www.americanbankingnews.com - May 18 at 8:21 PM
	FibroGen (FGEN) CEO Sells $2,053,937.52 in Stock www.americanbankingnews.com - May 18 at 8:05 PM
	-$0.58 EPS Expected for FibroGen (FGEN) This Quarter www.americanbankingnews.com - May 17 at 10:37 AM
	FibroGen (FGEN) Given Consensus Recommendation of "Buy" by Analysts www.americanbankingnews.com - May 17 at 1:39 AM
	FibroGen Upgraded By Mizuho On Continued R&D Progress finance.yahoo.com - May 16 at 9:25 AM
	FibroGen's (FGEN) "Buy" Rating Reaffirmed at Mizuho www.americanbankingnews.com - May 15 at 10:14 AM
	Mizuho Securities Upgrades FibroGen (FGEN) to Buy www.streetinsider.com - May 15 at 9:39 AM
	Zacks Investment Research Lowers FibroGen (FGEN) to Sell www.americanbankingnews.com - May 15 at 12:00 AM
	Q2 2018 Earnings Forecast for FibroGen (FGEN) Issued By Jefferies Group www.americanbankingnews.com - May 14 at 2:33 AM
	FibroGen (FGEN) to Post Q2 2018 Earnings of ($0.56) Per Share, Leerink Swann Forecasts www.americanbankingnews.com - May 14 at 2:24 AM
	FibroGen (FGEN) Director Sells $282,600.00 in Stock www.americanbankingnews.com - May 11 at 8:01 PM
	FibroGen (FGEN) Expected to Post FY2022 Earnings of $2.64 Per Share www.americanbankingnews.com - May 11 at 11:52 AM
	BRIEF-FibroGen Reports Q1 Loss Per Share $0.50 www.reuters.com - May 10 at 9:25 AM
	Edited Transcript of FGEN earnings conference call or presentation 9-May-18 9:00pm GMT finance.yahoo.com - May 10 at 9:24 AM
	FibroGen: 1Q Earnings Snapshot finance.yahoo.com - May 10 at 9:24 AM
	FibroGen (FGEN) Issues Quarterly Earnings Results www.americanbankingnews.com - May 9 at 9:32 PM
	FibroGen Reports First Quarter 2018 Financial Results finance.yahoo.com - May 9 at 4:44 PM
	Thomas B. Neff Sells 39,636 Shares of FibroGen (FGEN) Stock www.americanbankingnews.com - May 4 at 7:33 PM
	FibroGen (FGEN) Upgraded by Zacks Investment Research to Hold www.americanbankingnews.com - May 4 at 1:56 PM
	FibroGen (FGEN) Stock Rating Upgraded by ValuEngine www.americanbankingnews.com - May 4 at 12:13 AM
	FibroGen to Report First Quarter 2018 Financial Results on Wednesday, May 9, 2018 finance.yahoo.com - May 2 at 9:10 AM
	FibroGen (FGEN) Expected to Post Quarterly Sales of $28.23 Million www.americanbankingnews.com - May 1 at 2:02 AM
	FibroGen (FGEN) to Release Earnings on Monday www.americanbankingnews.com - April 30 at 7:23 AM
	-$0.51 EPS Expected for FibroGen (FGEN) This Quarter www.americanbankingnews.com - April 29 at 9:08 PM
	Consolidated Research: 2018 Summary Expectations for MGM Growth Properties, Reinsurance Group of America ... globenewswire.com - April 27 at 9:43 AM
	Form 4 FIBROGEN INC For: Apr 23 Filed by: Cotroneo Pat www.streetinsider.com - April 26 at 9:02 AM
	BRIEF-Fibrogen Inc CEO's 2017 Compensation Was $7.1 Million www.reuters.com - April 24 at 4:53 PM
	Form 4 FIBROGEN INC For: Apr 19 Filed by: Kurkijarvi Kalevi www.streetinsider.com - April 22 at 5:33 PM
	FibroGen (FGEN) Receives Average Recommendation of "Hold" from Analysts www.americanbankingnews.com - April 22 at 1:36 AM
	Form 4 FIBROGEN INC For: Apr 19 Filed by: Rosenkranz Roberto Pedro www.streetinsider.com - April 21 at 9:04 AM
	FibroGen (FGEN) Director Kalevi Kurkijarvi Sells 4,000 Shares www.americanbankingnews.com - April 20 at 7:40 PM
	FibroGen (FGEN) CEO Thomas B. Neff Sells 39,636 Shares www.americanbankingnews.com - April 19 at 10:10 PM
	Form 4 FIBROGEN INC For: Apr 16 Filed by: Yu K Peony www.streetinsider.com - April 19 at 9:10 AM
	Insider Selling: FibroGen (FGEN) Insider Sells 7,500 Shares of Stock www.americanbankingnews.com - April 18 at 7:28 PM
	FibroGen (FGEN) Stock Rating Lowered by BidaskClub www.americanbankingnews.com - April 14 at 10:53 PM
	FibroGen (FGEN) Expected to Announce Quarterly Sales of $28.23 Million www.americanbankingnews.com - April 14 at 2:02 AM
	Brokerages Anticipate FibroGen (FGEN) Will Post Earnings of -$0.51 Per Share www.americanbankingnews.com - April 12 at 9:16 PM
	FibroGen (FGEN) Rating Reiterated by Jefferies Group www.americanbankingnews.com - April 12 at 9:00 PM
	Stifel Nicolaus Raises FibroGen (FGEN) Price Target to $80.00 www.americanbankingnews.com - April 12 at 9:00 PM
	FibroGen (FGEN) Director Sells $279,540.00 in Stock www.americanbankingnews.com - April 11 at 10:37 PM
	William Blair Reiterates Outperform Rating for FibroGen (FGEN) www.americanbankingnews.com - April 11 at 6:13 PM
	A Look at FibroGen’s Cash Flow Generating Capacity finance.yahoo.com - April 9 at 9:25 AM

FibroGen (NASDAQ:FGEN) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

FibroGen (NASDAQ:FGEN) Income Statement, Balance Sheet and Cash Flow Statement

FibroGen (NASDAQ FGEN) Stock Chart for Saturday, May, 26, 2018

Loading chart…

This page was last updated on 5/26/2018 by MarketBeat.com Staff